An observational study in Myocardial Infarction, Acute Coronary Syndrome and Cocaine Use, sponsored by Hospital El Cruce. Recruiting at 1 site in Argentina. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-05.
Sponsored by Hospital El Cruce · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Myocardial Infarction with a site in Argentina — 3 open to participants now, 6 under way, 4 of them phase 3. Myocardial Infarction · Argentina.
Among the 34 studies in Myocardial Infarction with a site in Argentina, this one is one of 2 that started in 2023, is one of 7 observational ones, and was the 33rd registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →3 of the 34 studies in Myocardial Infarction with a site in Argentina are open now. Recruiting first, the newest first:
CSL Behring · Sites in Argentina, United States, Australia and 32 more countries
Ages 18+
McMaster University · Sites in Argentina, Canada
Ages 18+
A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 23
First in 2002; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is below the median of 568 across 814 observational studies indexed under Myocardial Infarction.
Median enrollment 5,700 across the 27 interventional studies, 982 across the 7 observational. Of the 26 that completed or were terminated, 15 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 34 have an industry lead sponsor. The 10 most frequent:
Hospital El Cruce is the lead sponsor of 15 studies on the registry; 6 are open to participants now.
Hospital El Cruce has 2 studies filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
1 of the studies in Myocardial Infarction with a site in Argentina that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06118281Phase 3Novo Nordisk A/SARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | 2027-01-29 |
Add it to your calendar (.ics) → With an account.
Among the 34 studies in Myocardial Infarction with a site in Argentina, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Cocaine use has increased in our country in recent decades. It is associated with cardiovascular events and early atherosclerotic disease. Acute coronary syndrome (ACS) is one of its most frequent and serious manifestations. There is a lack of scientific information on ACS associated with acute and chronic cocaine use in Argentina.
This study aims to describe the socioeconomic, clinical, and coronary angiographic characteristics, as well as the extent of atherosclerotic disease in patients with ACS associated with cocaine use, and to compare them with ACS not associated with cocaine use.
Methods: We propose an observational, analytical, single-center, two-phase study, with a retrospective and a prospective component. Patients with a diagnosis of ACS admitted to the coronary care unit of a high-complexity public hospital will be included. Clinical, biochemical, coronary angiographic, extracoronary atherosclerotic disease extension and prognostic variables will be described. These variables will be compared between patients with cocaine-associated ACS and non-cocaine-associated ACS.
General objective:
Specific objectives:
To characterize and compare between both groups:
Design:
A quantitative approach will be used, with an observational, analytical, single-center, two-stage design. In the retrospective stage, cases admitted from April 2019 to June 2023 for ACS will be included, based on data collected in the routine practice of the coronary care unit. In the prospective stage, all cases admitted to our institution for ACS from November 1, 2023, to November 2024 will be included.
Inclusion criteria:
Exclusion criteria:
Retrospective stage: patients who were not questioned about cocaine use. Prospective stage: patients who could not be interviewed to determine their history of cocaine use because of their clinical condition.
Procedures:
Two groups will be defined according to the history of cocaine use: cocaine-associated ACS and non-cocaine-associated ACS.
For the retrospective phase, all patients admitted to the coronary unit for ACS in the period established for the study will be reviewed. It is standard practice to ask about cardiovascular risk factors, history of substance use, including cocaine, and other clinical history. We expect to correctly identify cases of ACS associated and not associated with cocaine use.
In all cases included in both stages, the clinical, electrocardiographic, biochemical, and coronary angiographic characteristics and the extent of extra coronary atherosclerotic disease, complications, and prognosis will be described and compared between the two groups.
In the prospective phase of the study, where medically necessary, cardiac magnetic resonance imaging (MRI) will be performed to assess the extent of ACS-related and non-ACS-related myocardial necrosis and edema. Cardiac MRI findings will be compared between groups.
Clinical follow-up will be limited to hospitalization.
Main study variables and measurement instruments:
Statistical analysis:
Continuous variables will be described as mean and standard deviation in the case of normal distribution or median and interquartile range, and categorical variables will be described as numbers and percentages. Differences between groups for continuous variables will be evaluated with the T-test for variables with a normal distribution, and the Kruskal-Wallis test for nonparametric variables. Categorical variables will be compared using the chi-squared test and Fisher's exact test. Multiple logistic regression models will be developed to determine the independent association between cocaine use and the dependent variables of interest. Statistical analysis will be performed with the R Studio program.
Procedures to ensure the ethical aspects of the research:
All study procedures will be conducted following international ethical norms and standards to respect participant's rights and protect confidentiality.
In addition, all study procedures conform to the principles of the Declaration of Helsinki and CIOMS guidelines.
The research protocol was submitted for evaluation and approved by the Research Ethics Committee (REC) of the El Cruce Hospital.
For the retrospective stage, the research team will make every effort to contact patients who meet the inclusion criteria to request informed consent for their data to be analyzed, undertaking to guarantee the anonymity of personal data. For the prospective stage of the study, potentially eligible individuals will receive a detailed explanation of the objectives and procedures before enrollment. They will be asked to sign the informed consent form (ICF). Participation is voluntary and anonymity and confidentiality of information are compromised. At this stage, only cases that have signed the ICF will be included.
All information related to the study will be securely archived with access codes only available to the research team. Personal identification records will be kept separately from study records identified by code number. Data collection forms will be coded to maintain participant confidentiality. The local database will be protected with a password-protected access system. Study key codes linking participant identification numbers to other identifying information will be stored in a separate, locked file in a limited access area.
Patients with acute coronary syndrome admitted to the coronary care unit of a high-complexity hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For the prospective stage, it will be added:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Complexity and extent of coronary heart disease
The Syntax Score (Synergy Between PCI With Taxus and Cardiac Surgery) will be quantified in patients with and without a history of cocaine use. A higher Syntax Score indicates a more complex coronary disease as well as worse prognosis. Score values of 0 to 22 are considered low complexity, 23 to 32 moderate complexity and \>32 high complexity.
Time frame: During coronary angiography
Clinical presentation as STEAMI, or NSTEAMI or unstable angina
Differences between groups in clinical presentation as STEAMI, NSTEAMI or unstable angina will be based on the findings of the first electrocardiogram registred during admision, following the Fourth Universal Definition of Myocardial Infarction.
Time frame: Up to 24 hours of admission
Mortality
Total mortality
Time frame: During hospitalization (up to 30 days)
Severe complications
A combined ouctome including: resuscitated cardiac arrest, complex arrhythmia requiring electrical cardioversion, use of inotropes, or mechanical ventilatory support.
Time frame: During hospitalization (up to 30 days)
Extent of atherosclerotic vascular disease
The extent of extracoronary atherosclerotic vascular disease will be quantified by vascular Doppler of the carotids and lower limbs
Time frame: During hospitalization (up to 30 days)
Myocardial damage
The extent of ischemic and non-ischemic myocardial damage will be quantified by cardiac MRI.
Time frame: During hospitalization (up to 30 days)
Socioeconomic factors: unemployment
Unemployment (as a proportion) will be compared between patients with and without a history of cocaine use.
Time frame: During hospitalization (up to 30 days)
Socioeconomic factors: health insurance
Health insurance ownership (as a proportion) will be compared between patients with and without a history of cocaine use.
Time frame: During hospitalization (up to 30 days)
Socioeconomic factors: highest level of formal education
The highest level of formal education (as an ordinal variable from kindergarten = 1 to college = 8) will be compared between patients with and without a history of cocaine use.
Time frame: During hospitalization (up to 30 days)
Plan to share: Undecided — It hasn't been decided yet
Started Nov 2023 (actual). Primary completion is estimated for Nov 2024, 12 months after the start.
Of 298 non-industry observational studies under Myocardial Infarction, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 140. This study's planned 12 months is below that.
Counting every sponsor, half of 335 studies reached it within 48 months; a quarter within 18 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital El Cruce